– USA, ND – ImmunoPrecise Antibodies (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced the appointment of Barry Springer, Dirk Witters, and Chris Buyse to its Board of Directors.
Concurrently, the Company also announced the resignation of Greg Smith from the Board, effective immediately, and that Dr. James Kuo, Dr. Robert Burke, and Lisa Helbling will stand for re-election at the upcoming AGM.
About Barry A. Springer
Barry A. Springer is currently the principal at Springer Bio-Tech Consulting, LLC, and was previously VP of Janssen Strategy, Operations, and Innovation. Mr. Springer advised biotechnology and pharmaceutical companies providing executive-level strategic advice in the areas of biologics and small molecule drug discovery and development, and platform technology development.
About Dirk Witters
Dirk Witters founded Conanti Consult BV in 2019, an advisory boutique, where he, among other things, advises on the execution of acquisitions and capital raising assignments. Before that, Mr. Witters also served as an advisor to the founder of New Rhein Healthcare Investors, a private equity investment firm focused on healthcare therapeutics and medical devices. In addition to this more recent capital raising experience, Mr. Witters also spent 20+ years with KBC Group in Corporate and Investment Banking, including eight years as CEO of KBC France.
About Chris Buyse
Chris Buyse is currently a Board member and Chairman of the Audit Committee of Inventiva SA, a dual-listed company on Euronext Paris and Nasdaq, and a board member and member of the Audit Committee of Hyloris Pharmaceuticals a company listed on Euronext Brussels. Mr. Buyse has extensive experience in capital raising endeavors having co-founded FUND+ NV/SA, a private fund, investing in companies in the life sciences sector with a European focus, where he is currently a board member. He was also previously the CFO at ThromboGenics, a biopharmaceutical company listed on the Euronext Brussels Stock market, where he guided the company through its IPO and four capital raises (the raises totaling an aggregate of €500M).
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V.. The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in Bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets.
For more information: https://www.ipatherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.